US equities
|
MU
$989.49
▼-3.84%
SNDK
$1,485.93
▼-6.06%
META
$745.50
▲+3.73%
SPCX
$164.43
▲+1.14%
NVDA
$227.96
▼-0.58%
AMD
$596.40
▼-1.92%
AAPL
$340.96
▲+1.28%
MSFT
$538.71
▲+0.68%
MU
$989.49
▼-3.84%
SNDK
$1,485.93
▼-6.06%
META
$745.50
▲+3.73%
SPCX
$164.43
▲+1.14%
NVDA
$227.96
▼-0.58%
AMD
$596.40
▼-1.92%
AAPL
$340.96
▲+1.28%
MSFT
$538.71
▲+0.68%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Artiva Biotherapeutics, Inc. - Common Stock
(NQ:
ARTV
)
6.860
-0.080 (-1.15%)
Delayed Quote
Updated: 9:48 AM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Artiva Biotherapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
October 02, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
October 01, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
September 23, 2026
Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
September 08, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
September 02, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 06, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 23, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
June 08, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
May 19, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
May 19, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
May 14, 2026
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END
Via
FinancialNewsMedia
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 08, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 08, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
May 08, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
March 10, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
February 24, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
February 19, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
January 21, 2026
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Myseum (NASDAQ: MYSE) Realizes $6.8M in Asset Sale – Watch AMCI, ARTV, QIPT, SURG Today!
December 15, 2025
Via
AB Newswire
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
November 12, 2025
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 12, 2025
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
November 03, 2025
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
October 30, 2025
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
October 16, 2025
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
August 25, 2025
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
August 06, 2025
From
Artiva Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
